BridgeBio Pharma BBIO Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $502.08M+126% | $221.9M+2,285% | $9.3M-88.0% | $77.65M+11.4% | ||
| $20.96M+441% | $3.88M+58.5% | $2.45M-28.8% | $3.43M+25.6% | ||
| $481.11M+121% | $218.02M+3,080% | $6.86M-90.8% | $74.21M+10.8% | ||
| 95.8%-2.4pp | 98.3%+24.5pp | 73.7%-21.9pp | 95.6%-0.5pp | ||
| $451.95M-10.8% | $506.46M+11.1% | $455.71M+14.1% | $399.46M-11.4% | ||
| $531.23M+83.9% | $288.93M+91.9% | $150.59M+5.2% | $143.19M-25.5% | ||
| $1.03B+25.8% | $814.88M+32.1% | $616.67M+4.5% | $589.85M-8.7% | ||
| -$523.41M+11.7% | -$592.97M+2.4% | -$607.37M-18.6% | -$512.2M+11.2% | ||
| -104.2%+163pp | -267.2%+6,262pp | -6,528.8%-5,869pp | -659.6%+167pp | ||
| $79.13M-13.0% | $90.99M+11.9% | $81.29M+1.1% | $80.44M+72.0% | ||
| $19.85M+15.1% | $17.25M-4.4% | $18.04M+139% | $7.54M+566% | ||
| -$209.09M— | —— | —— | —— | ||
| -$72.61M-133% | -$31.18M— | $0— | $0— | ||
| -$21.16M+20.4% | -$26.59M— | $0— | $0+100% | ||
| -$732.94M-34.9% | -$543.35M+16.8% | -$653.25M-34.8% | -$484.65M+17.4% | ||
| -146%+98.9pp | -244.9%+6,777pp | -7,021.9%-6,398pp | -624.2%+217pp | ||
| -$3.77-31.4% | -$2.87+27.2% | -$3.94-20.5% | -$3.27+16.6% | ||
| -$3.77-31.4% | -$2.87+27.2% | -$3.94-20.5% | -$3.27+16.2% | ||
| 764M+3.1% | 740.9M+15.9% | 639.3M+8.7% | 588M+2.0% | ||
| 764M+3.1% | 740.9M+15.9% | 639.3M+8.7% | 588M— | ||
| $125.14M— | —— | $0— | —— | ||
| $43.06M+251% | $12.27M-29.3% | $17.37M— | —— | ||
| $21.35M+36.8% | $15.61M+96.9% | $7.93M— | —— | ||
| $502.08M+126% | $221.9M+2,285% | $9.3M-88.0% | $77.65M+11.4% | ||
| -$523.41M+11.7% | -$592.97M+2.4% | -$607.37M-18.6% | -$512.2M+11.2% | ||
| -$517.98M+11.7% | -$586.9M+2.3% | -$600.88M-18.9% | -$505.43M+11.5% | ||
| -$517.98M+11.7% | -$586.9M+2.3% | -$600.88M-18.9% | -$505.43M+11.5% | ||
| -103.2%+161pp | -264.5%+6,194pp | -6,458.9%-5,808pp | -650.9%+168pp | ||
| -$523.41M+11.7% | -$592.97M+2.4% | -$607.37M-18.6% | -$512.2M+11.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BridgeBio Pharma's revenue?
- BridgeBio Pharma (BBIO) generated $580.0M in revenue over the trailing twelve months, up 355.2% year over year.
- Is BridgeBio Pharma profitable?
- BridgeBio Pharma is not currently profitable: it reported a net loss of $729.9M over the trailing twelve months, a -125.9% net margin.
- What are BridgeBio Pharma's profit margins?
- Gross margin is 95.1% and operating margin is -90.5%, with a -125.9% net margin.
- What is BridgeBio Pharma's earnings per share?
- BridgeBio Pharma's diluted EPS over the trailing twelve months is $-3.73.
- Where does BridgeBio Pharma's income statement data come from?
- Every line is extracted from BridgeBio Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
